Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias (Q39380134)

11 September 2017

title

Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias (English)

1 reference

11 September 2017

Matthias Rarey

11

0 references

author name string

Patrick Ziegler

1

1 reference

11 September 2017

Tuhama Chahoud

2

1 reference

11 September 2017

Thomas Wilhelm

3

1 reference

11 September 2017

Nora Pällman

4

1 reference

11 September 2017

Melanie Braig

5

1 reference

11 September 2017

Valeska Wiehle

6

1 reference

11 September 2017

Susanne Ziegler

7

1 reference

11 September 2017

Marcus Schröder

8

1 reference

11 September 2017

Chris Meier

9

1 reference

11 September 2017

Adrian Kolodzik

10

1 reference

11 September 2017

Jens Panse

12

1 reference

11 September 2017

Joachim Hauber

13

1 reference

11 September 2017

Stefan Balabanov

14

1 reference

11 September 2017

Tim H Brümmendorf

15

1 reference

11 September 2017

publication date

14 March 2012

1 reference

Investigational New Drugs

11 September 2017

published in

1 reference

11 September 2017

volume

30

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

2274-2283

1 reference

The biology of cancer stem cells

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Molecular mechanisms of transformation by the BCR-ABL oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Targeted CML therapy: controlling drug resistance, seeking cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

The archaebacterial hypusine-containing protein. Structural features suggest common ancestry with eukaryotic translation initiation factor 5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

eIF5A promotes translation elongation, polysome disassembly and stress granule assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Effects of 1,8-diaminooctane on the FIV Rev regulatory system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Screening assay for the identification of deoxyhypusine synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Inhibition of cell growth through inactivation of eukaryotic translation initiation factor 5A (eIF5A) by deoxyspergualin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Trypanocidal 1,3-arylene diketone bis(guanylhydrazone)s. Structure-activity relationships among substituted and heterocyclic analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Inhibitory effect of imatinib on normal progenitor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Is hypusine essential for eukaryotic cell proliferation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Identification and characterization of eukaryotic initiation factor 5A-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Independent roles of eIF5A and polyamines in cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9810-1

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach

21 January 2018

1 reference

12 December 2020

The biosynthesis of protein-bound hypusine (N epsilon -(4-amino-2-hydroxybutyl)lysine). Lysine as the amino acid precursor and the intermediate role of deoxyhypusine (N epsilon -(4-aminobutyl)lysine)

1 reference

12 December 2020

An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality

1 reference

12 December 2020

Detection of BCR-ABL mutations and resistance to imatinib mesylate.

1 reference

12 December 2020

Suppressor cells induced by donor-specific transfusion and deoxyspergualin in rat cardiac xenografts

1 reference

12 December 2020

Synthesis of (-)-15-deoxyspergualin and (-)-spergualin-15-phosphate

1 reference

12 December 2020

Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway

1 reference

12 December 2020

Eukaryotic initiation factor 4D, the hypusine-containing protein, is conserved among eukaryotes.

1 reference

12 December 2020

Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding

1 reference

12 December 2020

Chronic myelogenous leukemia: recent advances

1 reference

12 December 2020

10.1007/S10637-012-9810-1

Identifiers

DOI

1 reference

11 September 2017

1 reference